Director at Mereo BioPharma (MREO) awarded 66,000 share options

Rhea-AI Filing Summary

WYZGA MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.

Mereo BioPharma Group plc director Michael S. Wyzga reported receiving a grant of 66,000 share options on February 26, 2026. These options are a right to buy shares and were awarded for no cash payment at grant. The award vests in substantially equal monthly installments over one year from the February 26, 2026 grant date. Each American Depositary Share represents five ordinary shares of the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WYZGA MICHAEL S

(Last) (First) (Middle)

C/O MEREO BIOPHARMA GROUP PLC

4TH FLOOR, ONE CAVENDISH PLACE

(Street)

LONDON X0 W1G 0QF

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mereo BioPharma Group plc [ MREO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Options (Right to buy)	$0.39	02/26/2026		A		66,000		(1)	02/26/2036	American Depositary Shares(2)	66,000	$0	66,000	D

Explanation of Responses:

1. Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.

2. Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

	/s/ Christine Fox, by power of attorney	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Mereo BioPharma (MREO) disclose for Michael S. Wyzga?

Mereo BioPharma disclosed that director Michael S. Wyzga received a grant of 66,000 share options on February 26, 2026. The options are a right to buy shares and were awarded as compensation rather than a cash purchase in the market.

How do the new options for Mereo BioPharma (MREO) director vest?

The 66,000 share options granted to director Michael S. Wyzga vest in substantially equal monthly installments over one year. The vesting period runs from the February 26, 2026 grant date, spreading the award over 12 months rather than becoming fully exercisable immediately.

What type of security did the Mereo BioPharma (MREO) Form 4 report?

The Form 4 reports a derivative security described as share options, giving a right to buy Mereo BioPharma shares. These options were granted directly to director Michael S. Wyzga and increase his derivative holdings to 66,000 share options after the reported transaction.

Did Michael S. Wyzga buy or sell Mereo BioPharma (MREO) shares in this filing?

The filing shows an acquisition through a grant of 66,000 share options, not a market purchase or sale of existing shares. The transaction is coded as an award, reflecting compensation rather than open-market trading activity by the director.

How are Mereo BioPharma (MREO) ordinary shares represented in ADS form?

Each American Depositary Share of Mereo BioPharma represents five ordinary shares of the issuer. This ratio means investors holding ADSs indirectly hold a multiple of the company’s ordinary shares through the depositary structure referenced in the filing’s footnote.